[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334930-105":59,"doc-detail-334930-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","endocrine-therapy-in-advanced-high-grade-ovarian-cancer-real-life-data-from-a-multicenter-study-and-a-review-of-the-literature","Endocrine Therapy in Advanced High-Grade Ovarian Cancer - Real-Life Data from a Multicenter Study and a Review of the Literature","","Endocrine therapy in advanced high-grade ovarian cancer addresses the clinical challenge of frequent relapse and poor outcomes in platinum-resistant disease, where further chemotherapy lines offer limited benefit and often worsen quality of life. A multicenter retrospective study evaluated endocrine treatment use in high-grade ovarian epithelial carcinomas from 2010 to 2020. Eighty-one patients were included, with 35% disease control and 10% symptom improvement, and stabilization beyond six months in 23.5%. Median overall survival from diagnosis was 62.6 months, while multivariate analysis linked progression-free survival to platinum sensitivity, R0 resection, and maintenance hormone therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/endocrine-therapy-in-advanced-high-grade-ovarian-cancer-real-life-data-from-a-multicenter-study-and-a-review-of-the-literature/334930/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/endocrine-therapy-in-advanced-high-grade-ovarian-cancer-real-life-data-from-a-multicenter-study-and-a-review-of-the-literature/334930.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical problem does endocrine therapy target in advanced high-grade ovarian cancer?","Question",{"text":112,"@type":113},"In advanced disease, relapses are common and prognosis is poor, especially when cancer becomes platinum resistant. Subsequent chemotherapy lines often provide limited efficacy and are poorly tolerated, leading to quality-of-life deterioration, motivating hormonal treatment rationale.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the endocrine treatment evidence generated in this study?",{"text":117,"@type":113},"The study used a multicenter, retrospective design evaluating endocrine treatment for high-grade ovarian epithelial carcinomas treated between 2010 and 2020.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors predicted better progression-free survival in multivariate analysis?",{"text":121,"@type":113},"Three factors were statistically significant: platinum sensitivity, an R0 surgical resection, and hormone therapy delivered as maintenance therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334930,1790169842,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":4},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature  \nMarine Aubert1, Laurent Mathiot2, Hélène Vegas1, Lobna Ouldamer3, Claude Linassier1, PauleAugereau4, François Bocquet5, Jean-Sébastien Frenel2, Mathilde Cancel*, 1,  \n1Department of Medical Oncology, CHU Bretonneau Tours, Tours, France,  \n2Department of Medical Oncology, Institut de Cancérologie de l’Ouest, Site René Gauducheau, Saint Herblain, France, 3Department of Gynecology, CHU Bretonneau Tours, Tours, France,  \n4Department of Medical Oncology, Institut de Cancérologie de l’Ouest, Site Paul Papin, Angers, France,  \n5Data Factory and Analytics, Institut de Cancérologie de l’Ouest, Site René Gauducheau, Saint Herblain, France  \n*Corresponding author: Mathilde Cancel, Department of Medical Oncology, CHU Bretonneau Tours, 2 Bd Tonnellé, 37044 Tours, France ([m.cancel@chu-tours.fr](m.cancel@chu-tours.fr)) .  \nAbstract  \nBackground: In women, ovarian cancer is the eighth most frequent cancer in incidence and mortality. It is often diagnosed at advanced stages; relapses are frequent, with a poor prognosis. When platinum resistant, subsequent lines of chemotherapy are of limited effect and often poorly tolerated, leading to quality of life deterioration. Various studies suggest a hormonal role in ovarian carcinogenesis, with a rationale for endocrine therapy in these cancers.  \nPatients and Methods: This multicenter, retrospective study assessed the use of endocrine treatment for high-grade ovarian epithelial carcinomas treated between 2010 and 2020.  \nResults: Eighty-one patients with ovarian cancers were included. The median duration of platinum sensitivity was 29 months. We observed a 35% disease control rate with endocrine therapy, and 10% reported symptom improvement. For 19 patients (23 . 5%), the disease was stabilized for more than 6 months. Median overall survival from diagnosis was 62.6 months. Regarding endocrine therapy predictive factors of response, ina multivariate analysis, 3 factors were statistically significant in favoring progression-free survival: platinum sensitivity ( P = .021), an R0 surgical resection ( P = .020), and the indication for hormone therapy being maintenance therapy ( P = .002)  \nConclusion: This study shows real-life data on endocrine therapy in ovarian cancer. As it is a low-cost treatment with many advantages such as its oral administration and its safety, it may be an option to consider. A perspective lies in the search for cofactors to aim as future therapeutic targets to improve the effectiveness of hormone treatment by means of combination therapy.  \nKey words: ovarian epithelial carcinoma; aromatase inhibitors; estrogen receptor antagonists; platinum sensitivity.  \nAbbreviations: AI, aromatase inhibitors; BRCA, BReast Cancer gene; CA125, cancer antigen 125; CNIL,“Commission Nationale de l’Informatique et des Libertés”; DCR, disease control rate; DOT1L, distuptor of telomeric silencing 1-like; EGFR, epidermal growth factor receptor; ERα, estrogen receptor alpha; FIGO, International Federation of Gynecology and Obstetrics; HER2, human epidermal growth factor receptor-2; HR, hazard ratio; NK, not known; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PM, disease progression; PR, partial response; RR, relative risk; SPSS, Statistical Package for the Social Sciences; TCGA, The Cancer Genome Atlas Program  \nImplications for Practice  \nVarious studies suggest a hormonal role in ovarian carcinogenesis, with a rationale for endocrine therapy in these cancers. This multicenter retrospective study on 81 patients with ovarian cancers expressing hormonal receptor, shows that endocrine therapy is feasible with some efficacy. As it is a low-cost treatment, well tolerated, it may be an option to consider in ovarian cancer, particularly for patients not eligible for other standard treatments such as chemotherapy or PARP inhibitors.  \nBackg","cbCaisQIDc5ogG8z","https://ap.wps.com/l/cbCaisQIDc5ogG8z","pdf",375474,"English","# Abstract\n## Background\n## Patients and Methods\n## Results\n## Conclusion\n# Implications for Practice\n# Background","[{\"question\":\"What clinical problem does endocrine therapy target in advanced high-grade ovarian cancer?\",\"answer\":\"In advanced disease, relapses are common and prognosis is poor, especially when cancer becomes platinum resistant. Subsequent chemotherapy lines often provide limited efficacy and are poorly tolerated, leading to quality-of-life deterioration, motivating hormonal treatment rationale.\"},{\"question\":\"How was the endocrine treatment evidence generated in this study?\",\"answer\":\"The study used a multicenter, retrospective design evaluating endocrine treatment for high-grade ovarian epithelial carcinomas treated between 2010 and 2020.\"},{\"question\":\"Which factors predicted better progression-free survival in multivariate analysis?\",\"answer\":\"Three factors were statistically significant: platinum sensitivity, an R0 surgical resection, and hormone therapy delivered as maintenance therapy.\"}]","Endocrine Therapy in Advanced High-Grade Ovarian Cancer - Real-Life Data from a Multicenter Study and a Review of the Literature | PDF",1790008884]